Mexico Infectious Disease Therapeutics Market Analysis

Mexico Infectious Disease Therapeutics Market Analysis


$ 3999

By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes Laboratories, BIRMEX and Liomont Laboratories. The Infectious Disease Therapeutics market in Mexico is segmented into different therapeutic areas and different diseases type. The major factors affecting the Mexico infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of Mexico.

ID: IN10MXPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Dr. Vishwa Modhia

Buy Now

Mexico Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030.

Mexico is an upper middle-income, developing country located in North America with a North Pacific Ocean, Gulf of Mexico, and Caribbean Sea coastline. Mexico is a vast country with a complex healthcare system that differs by location.

The government has achieved tremendous progress in reducing the spread of infectious diseases, but some infectious diseases, particularly those associated with poverty, such as tuberculosis (TB), dengue fever, and Chagas disease, continue to pose obstacles. Mexico has an intermediate risk of infectious illnesses, according to the World Factbook. Mexico's government spends 6.2% of its GDP on healthcare.

Mexico Infectious Disease Therapeutics Market Analysis

Market Dynamics

Market Growth Drivers Analysis

Infectious disorders such as tuberculosis, HIV/AIDS, and dengue fever are prevalent in Mexico. As a result, there is a high demand for effective treatments and prevention techniques. Mexico has a large population, is geographically close to the US economy, and has a comparatively low labour cost. These aspects could boost Mexico's infectious disease therapeutics market.

Market Restraints

In Mexico, the infectious illness therapies industry is frequently dominated by other pharmaceutical corporations as well as alternative therapy modalities such as traditional medicine. Companies may find it challenging to obtain market share and generate significant commercial growth as a result of this. Mexico has a wide economic gap, a significant level of informality in the labour sector, and rising criminality. These factors may deter new entrants into the Mexico infectious disease therapeutics market.

Competitive Landscape

Key Players

  • Silanes Laboratories: Silanes is a pharmaceutical company based in Mexico that develops and manufactures drugs for various diseases, including infectious diseases
  • Liomont Laboratories: Liomont is a pharmaceutical company based in Mexico that specializes in developing and manufacturing vaccines and other drugs for infectious diseases
  • Laboratorios PiSA: PiSA is a pharmaceutical company based in Mexico that develops and manufactures drugs for various diseases, including infectious diseases
  • Laboratorios de Biológicos y Reactivos de México (BIRMEX): BIRMEX is a government-owned company based in Mexico that produces and distributes vaccines and other biological products for infectious diseases
  • Laboratorios de Biología Molecular Inmunoquímica (LABIMI)
  • Instituto Nacional de Enfermedades Respiratorias (INER)

Recent Notable Updates

August 2022: Birmex and the Indian pharmaceutical business Cipla signed a Strategic Alliance and Technology Transfer Agreement today. Marcelo Ebrard Casaubon, Secretary of Foreign Relations, travelled to India with the goal of boosting the Mexican health system through the negotiation of technology transfer agreements to produce vaccines and medications in Mexico.

May 2021: The Liomont factory will supply Mexico and Argentina, in addition to the other Latin American nations with which AstraZeneca has contracts.

Healthcare Policies and Reimbursement Scenarios

Several bodies in Mexico regulate and reimburse infectious illness medicines, including the Federal Commission for Protection against Health Risks (COFEPRIS) and the Mexican Social Security Institute (IMSS). In Mexico, the public health system, which comprises the IMSS and the Institute of Security and Social Services for State Workers (ISSSTE), has a considerable influence on the reimbursement process for infectious disease treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

  • Vaccines
  • Drugs

By Applications (Revenue, USD Billion):

  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Malaria
  • Tuberculosis
  • Others

By Disease Type (Revenue, USD Billion):

  • Viral Diseases
  • Bacterial Diseases
  • Fungal Diseases
  • Parasitic Diseases
  • Others

By Target Organism (Revenue, USD Billion):

  • Antibiotics
  • Antivirals
  • Antifungals
  • Anti-Parasitic
  • Others

By End User (Revenue, USD Billion):

  • Hospitals and Clinics
  • Ambulatory Care Centers
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.

By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030.

In Mexico, the regulation and reimbursement of infectious disease therapeutics are overseen by several entities, including the Federal Commission for Protection against Health Risks (COFEPRIS) and the Mexican Social Security Institute (IMSS).

Infectious Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes Laboratories, BIRMEX and Liomont Laboratories.


Last updated on: 13 March 2023
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up